Weight loss injections, particularly GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro), have revolutionized obesity management, but questions about their cardiovascular safety remain a priority for patients and clinicians
Not every researcher benefits from triple agonism
Snyder added that weight-loss medications should be considered as just one tool in a comprehensive plan
Others come to it from wound-healing, connective-tissue, or barrier-model work where inflammation and remodeling are both part of the endpoint
But some people experience appetite suppression so aggressively that they struggle to eat enough to meet basic nutritional needs
Sciogli tutti i tuoi dubbi e prenota adesso la tua prima visita